際際滷shows by User: AndreaPMalizia / http://www.slideshare.net/images/logo.gif 際際滷shows by User: AndreaPMalizia / Mon, 21 Nov 2016 15:01:30 GMT 際際滷Share feed for 際際滷shows by User: AndreaPMalizia Curis, snapshot November 2016 /slideshow/curis-snapshot-november-2016/69358842 curis-161121150130
Curis, snapshot of the current development and financial forecast of its leading compound CUDC-907. CUDC-907 is designed to inhibit HDACs 1, 2, 3, 6 and 10 and PI3K-alpha, delta and beta isoforms. CUDC-907 can be indicated for antitumor activity in various hematologic tumor models, such as non-Hodgkin's lymphoma and multiple myeloma. Of interest, CA-170 is an oral small molecule drug candidate designed to selectively target programmed death ligand 1 (PD-L1) and VISTA checkpoint proteins, both of which independently function as negative regulators of immune activation.]]>
Curis, snapshot of the current development and financial forecast of its leading compound CUDC-907. CUDC-907 is designed to inhibit HDACs 1, 2, 3, 6 and 10 and PI3K-alpha, delta and beta isoforms. CUDC-907 can be indicated for antitumor activity in various hematologic tumor models, such as non-Hodgkin's lymphoma and multiple myeloma. Of interest, CA-170 is an oral small molecule drug candidate designed to selectively target programmed death ligand 1 (PD-L1) and VISTA checkpoint proteins, both of which independently function as negative regulators of immune activation.]]> Mon, 21 Nov 2016 15:01:30 GMT /slideshow/curis-snapshot-november-2016/69358842 AndreaPMalizia@slideshare.net(AndreaPMalizia) Curis, snapshot November 2016 AndreaPMalizia Curis, snapshot of the current development and financial forecast of its leading compound CUDC-907. CUDC-907 is designed to inhibit HDACs 1, 2, 3, 6 and 10 and PI3K-alpha, delta and beta isoforms. CUDC-907 can be indicated for antitumor activity in various hematologic tumor models, such as non-Hodgkin's lymphoma and multiple myeloma. Of interest, CA-170 is an oral small molecule drug candidate designed to selectively target programmed death ligand 1 (PD-L1) and VISTA checkpoint proteins, both of which independently function as negative regulators of immune activation. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/curis-161121150130-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Curis, snapshot of the current development and financial forecast of its leading compound CUDC-907. CUDC-907 is designed to inhibit HDACs 1, 2, 3, 6 and 10 and PI3K-alpha, delta and beta isoforms. CUDC-907 can be indicated for antitumor activity in various hematologic tumor models, such as non-Hodgkin&#39;s lymphoma and multiple myeloma. Of interest, CA-170 is an oral small molecule drug candidate designed to selectively target programmed death ligand 1 (PD-L1) and VISTA checkpoint proteins, both of which independently function as negative regulators of immune activation.
Curis, snapshot November 2016 from Andrea P. Malizia. PhD, MBA
]]> 283 4 https://cdn.slidesharecdn.com/ss_thumbnails/curis-161121150130-thumbnail.jpg?width=120&height=120&fit=bounds document 000000 http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Epilepsy, Industry Snapshot. Oct 17-25. /slideshow/epilepsy-market-weekly-report-oct-1725-competitive-intelligence/67817231 newsreport-161029024838
Epilepsy market -snapshot- , weekly report Oct 17-25. News and market analysis of pharmaceutical companies. Competitive Intelligence.]]>
Epilepsy market -snapshot- , weekly report Oct 17-25. News and market analysis of pharmaceutical companies. Competitive Intelligence.]]> Sat, 29 Oct 2016 02:48:37 GMT /slideshow/epilepsy-market-weekly-report-oct-1725-competitive-intelligence/67817231 AndreaPMalizia@slideshare.net(AndreaPMalizia) Epilepsy, Industry Snapshot. Oct 17-25. AndreaPMalizia Epilepsy market -snapshot- , weekly report Oct 17-25. News and market analysis of pharmaceutical companies. Competitive Intelligence. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/newsreport-161029024838-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Epilepsy market -snapshot- , weekly report Oct 17-25. News and market analysis of pharmaceutical companies. Competitive Intelligence.
Epilepsy, Industry Snapshot. Oct 17-25. from Andrea P. Malizia. PhD, MBA
]]> 315 8 https://cdn.slidesharecdn.com/ss_thumbnails/newsreport-161029024838-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Sage Therapeutics, Competitive Strategy Report /slideshow/sage-therapeutics-competitive-strategy-report/66570008 sagereport-160929174235
Competitive Strategy report for SAGE Therapeutics, October 2016, with insights from Thomson Reuters Cortellis.]]>
Competitive Strategy report for SAGE Therapeutics, October 2016, with insights from Thomson Reuters Cortellis.]]> Thu, 29 Sep 2016 17:42:34 GMT /slideshow/sage-therapeutics-competitive-strategy-report/66570008 AndreaPMalizia@slideshare.net(AndreaPMalizia) Sage Therapeutics, Competitive Strategy Report AndreaPMalizia Competitive Strategy report for SAGE Therapeutics, October 2016, with insights from Thomson Reuters Cortellis. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/sagereport-160929174235-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Competitive Strategy report for SAGE Therapeutics, October 2016, with insights from Thomson Reuters Cortellis.
Sage Therapeutics, Competitive Strategy Report from Andrea P. Malizia. PhD, MBA
]]> 1253 8 https://cdn.slidesharecdn.com/ss_thumbnails/sagereport-160929174235-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Alnylam May 2016 /AndreaPMalizia/alnylam-may-2016-66152129 alnylammay2016-160919024001
Competitive report for Alnylam Pharmaceuticals -May 2016- using an adapted version of strategy framework and infographics.]]>
Competitive report for Alnylam Pharmaceuticals -May 2016- using an adapted version of strategy framework and infographics.]]> Mon, 19 Sep 2016 02:40:01 GMT /AndreaPMalizia/alnylam-may-2016-66152129 AndreaPMalizia@slideshare.net(AndreaPMalizia) Alnylam May 2016 AndreaPMalizia Competitive report for Alnylam Pharmaceuticals -May 2016- using an adapted version of strategy framework and infographics. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/alnylammay2016-160919024001-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Competitive report for Alnylam Pharmaceuticals -May 2016- using an adapted version of strategy framework and infographics.
Alnylam May 2016 from Andrea P. Malizia. PhD, MBA
]]> 223 3 https://cdn.slidesharecdn.com/ss_thumbnails/alnylammay2016-160919024001-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 https://cdn.slidesharecdn.com/profile-photo-AndreaPMalizia-48x48.jpg?cb=1525889137 Strategist with a passion for leveraging decision making methods, strategy-formulation analytical framework and management science to capture value in a competitive market. https://cdn.slidesharecdn.com/ss_thumbnails/curis-161121150130-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/curis-snapshot-november-2016/69358842 Curis, snapshot Novemb... https://cdn.slidesharecdn.com/ss_thumbnails/newsreport-161029024838-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/epilepsy-market-weekly-report-oct-1725-competitive-intelligence/67817231 Epilepsy, Industry Sna... https://cdn.slidesharecdn.com/ss_thumbnails/sagereport-160929174235-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/sage-therapeutics-competitive-strategy-report/66570008 Sage Therapeutics, Com...